Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Amortizatization of Intangibles (2023 - 2025)

Historic Amortizatization of Intangibles for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $352000.0.

  • Compass Therapeutics' Amortizatization of Intangibles rose 931.68% to $352000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 1517.57%. This contributed to the annual value of $1.2 million for FY2024, which is 226.7% down from last year.
  • Latest data reveals that Compass Therapeutics reported Amortizatization of Intangibles of $352000.0 as of Q3 2025, which was up 931.68% from $267000.0 recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Amortizatization of Intangibles peaked at $352000.0 during Q3 2025, and registered a low of $219000.0 during Q4 2024.
  • For the 3-year period, Compass Therapeutics' Amortizatization of Intangibles averaged around $290727.3, with its median value being $302000.0 (2023).
  • Per our database at Business Quant, Compass Therapeutics' Amortizatization of Intangibles crashed by 2866.45% in 2024 and then surged by 931.68% in 2025.
  • Over the past 3 years, Compass Therapeutics' Amortizatization of Intangibles (Quarter) stood at $307000.0 in 2023, then dropped by 28.66% to $219000.0 in 2024, then surged by 60.73% to $352000.0 in 2025.
  • Its Amortizatization of Intangibles was $352000.0 in Q3 2025, compared to $267000.0 in Q2 2025 and $224000.0 in Q1 2025.